{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:59:32Z","timestamp":1768975172484,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,7]]},"DOI":"10.7759\/cureus.64038","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T03:46:26Z","timestamp":1720410386000},"source":"Crossref","is-referenced-by-count":3,"title":["Assessing the Renal Outcomes of Semaglutide in Diabetic Kidney Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Shuja ur","family":"Rehman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil Deep","family":"Kolanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Muaz","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husnain","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeeshan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maham","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryyam","family":"Liaqat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Asad","family":"Sarwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Faqeer Hussain","family":"Bokhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fazeel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyal","family":"Bakht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154890","article-title":"Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies","volume":"124","author":"Ricciardi CA","year":"2021","unstructured":"Ricciardi CA, Gnudi L. Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies. Metabolism. 2021, 124:154890. 10.1016\/j.metabol.2021.154890","journal-title":"Metabolism"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.10.003","article-title":"Diagnosis of diabetic kidney disease: State of the art and future perspective","volume":"8","author":"Persson F","year":"2018","unstructured":"Persson F, Rossing P. Diagnosis of diabetic kidney disease: State of the art and future perspective. Kidney Int Suppl (2011). 2018, 8:2-7. 10.1016\/j.kisu.2017.10.003","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref3","article-title":"Diabetic kidney disease: World wide difference of prevalence and risk factors","volume":"5","author":"Gheith O","year":"2015","unstructured":"Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: World wide difference of prevalence and risk factors. J Nephropharmacol. 2015, 5:49-56.","journal-title":"J Nephropharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0723","article-title":"Chronic kidney disease testing among at-risk adults in the U.S. remains low: Real-world evidence from a National Laboratory Database","volume":"44","author":"Alfego D","year":"2021","unstructured":"Alfego D, Ennis J, Gillespie B, et al.. Chronic kidney disease testing among at-risk adults in the U.S. remains low: Real-world evidence from a National Laboratory Database. Diabetes Care. 2021, 44:2025-32. 10.2337\/dc21-0723","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132943","article-title":"Management of kidney failure in patients with diabetes mellitus: What are the best options?","volume":"10","author":"Buades JM","year":"2021","unstructured":"Buades JM, Craver L, Del Pino MD, et al.. Management of kidney failure in patients with diabetes mellitus: What are the best options?. J Clin Med. 2021, 10:2943. 10.3390\/jcm10132943","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.1.80","article-title":"Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population","volume":"29","author":"Chung H","year":"2023","unstructured":"Chung H, Crowe CL, Kong SX, et al.. Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population. J Manag Care Spec Pharm. 2023, 29:80-9. 10.18553\/jmcp.2023.29.1.80","journal-title":"J Manag Care Spec Pharm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra MK","year":"2022","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022, 23:521-39. 10.1007\/s11154-021-09699-1","journal-title":"Rev Endocr Metab Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/11795514231213568","article-title":"Efficacy and tolerability of semaglutide in patients with type-2 diabetes mellitus: Experience of a tertiary care hospital, Pakistan","volume":"16","author":"Wajid M","year":"2023","unstructured":"Wajid M, Sattar S, Khalid F, Masood MQ. Efficacy and tolerability of semaglutide in patients with type-2 diabetes mellitus: Experience of a tertiary care hospital, Pakistan. Clin Med Insights Endocrinol Diabetes. 2023, 16:11795514231213568. 10.1177\/11795514231213568","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/8755122518790925","article-title":"Semaglutide for the treatment of type 2 diabetes mellitus","volume":"34","author":"Miles KE","year":"2018","unstructured":"Miles KE, Kerr JL. Semaglutide for the treatment of type 2 diabetes mellitus. J Pharm Technol. 2018, 34:281-9. 10.1177\/8755122518790925","journal-title":"J Pharm Technol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12030657","article-title":"Transforming diabetes care: The molecular pathways through which GLP1-RAs impact the kidneys in diabetic kidney disease","volume":"12","author":"Rroji M","year":"2024","unstructured":"Rroji M, Spasovski G. Transforming diabetes care: The molecular pathways through which GLP1-RAs impact the kidneys in diabetic kidney disease. Biomedicines. 2024, 12:657. 10.3390\/biomedicines12030657","journal-title":"Biomedicines"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55060233","article-title":"GLP-1 receptor agonists and kidney protection","volume":"55","author":"Greco EV","year":"2019","unstructured":"Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S. GLP-1 receptor agonists and kidney protection. Medicina (Kaunas). 2019, 55:233. 10.3390\/medicina55060233","journal-title":"Medicina (Kaunas)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8163153","article-title":"Renoprotective effects of incretin-based therapy in diabetes mellitus","volume":"2021","author":"Yaribeygi H","year":"2021","unstructured":"Yaribeygi H, Atkin SL, Montecucco F, Jamialahmadi T, Sahebkar A. Renoprotective effects of incretin-based therapy in diabetes mellitus. Biomed Res Int. 2021, 2021:8163153. 10.1155\/2021\/8163153","journal-title":"Biomed Res Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1889","article-title":"Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: Exploratory analysis from the STEP 1, 2, and 3 trials","volume":"46","author":"Heerspink HJ","year":"2023","unstructured":"Heerspink HJ, Apperloo E, Davies M, et al.. Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: Exploratory analysis from the STEP 1, 2, and 3 trials. Diabetes Care. 2023, 46:801-10. 10.2337\/dc22-1889","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Bhatta M, Davies M, et al.. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023, 25:468-78. 10.1111\/dom.14890","journal-title":"Diabetes Obes Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2020.10.008","article-title":"Acute kidney injury associated with semaglutide","volume":"3","author":"Leehey DJ","year":"2021","unstructured":"Leehey DJ, Rahman MA, Borys E, Picken MM, Clise CE. Acute kidney injury associated with semaglutide. Kidney Med. 2021, 3:282-5. 10.1016\/j.xkme.2020.10.008","journal-title":"Kidney Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac096","article-title":"Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice","volume":"15","author":"Aviles Bueno B","year":"2022","unstructured":"Aviles Bueno B, Soler MJ, Perez-Belmonte L, Jimenez Millan A, Rivas Ruiz F, Garcia de Lucas MD. Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice. Clin Kidney J. 2022, 15:1593-600. 10.1093\/ckj\/sfac096","journal-title":"Clin Kidney J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100561","article-title":"Semaglutide-associated acute interstitial nephritis: A case report","volume":"4","author":"Borkum M","year":"2022","unstructured":"Borkum M, Lau W, Blanco P, Farah M. Semaglutide-associated acute interstitial nephritis: A case report. Kidney Med. 2022, 4:100561. 10.1016\/j.xkme.2022.100561","journal-title":"Kidney Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1240279","article-title":"Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: A multicenter real-world study","volume":"14","author":"Garc\u00eda de Lucas MD","year":"2023","unstructured":"Garc\u00eda de Lucas MD, Caballero I, Fern\u00e1ndez-Garc\u00eda JC, et al.. Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: A multicenter real-world study. Front Endocrinol (Lausanne). 2023, 14:1240279. 10.3389\/fendo.2023.1240279","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1031_23","article-title":"The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus","volume":"13","author":"Algarni AA","year":"2024","unstructured":"Algarni AA, Alqarni FS, Shalaby HA. The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus. J Family Med Prim Care. 2024, 13:532-6. 10.4103\/jfmpc.jfmpc_1031_23","journal-title":"J Family Med Prim Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13440","article-title":"Effects of oral semaglutide on renal function in diabetic kidney disease: A short-term clinical study","volume":"38","author":"Mima A","year":"2024","unstructured":"Mima A, Kidooka S, Nakamoto T, et al.. Effects of oral semaglutide on renal function in diabetic kidney disease: A short-term clinical study. In Vivo. 2024, 38:308-12. 10.21873\/invivo.13440","journal-title":"In Vivo"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/264504-assessing-the-renal-outcomes-of-semaglutide-in-diabetic-kidney-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T03:46:29Z","timestamp":1720410389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/264504-assessing-the-renal-outcomes-of-semaglutide-in-diabetic-kidney-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,7]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.64038","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,7]]}}}